by admin | Jul 16, 2026 | English
Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, is conditionally authorized by the European Commission for the treatment of certain hematological malignancies FarmaMondo has been granted distribution rights for Zemcelpro® in Argentina, Hong Kong and...
by admin | Jun 10, 2026 | English
Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if approved by Health Canada) Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing...
by admin | Mar 10, 2026 | English
Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT...
by admin | Feb 16, 2026 | English
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, February 16, 2026 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic...
by admin | Dec 19, 2025 | English
MONTREAL, December 19, 2025 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, announced the publication in the journal Transplantation and Cell...
